Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.44 |
| ▸ | PRNP | P04156 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 6/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | MMP7 | P09237 | 2/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.39 |
| ▸ | ACP3 | P15309 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7052614 | 0.82 | METAP2 (0.41) | MMP1MMP13ACP3NPC1 | |
| SCHEMBL7046958 | 0.82 | MMP1 (0.44) | MMP1MMP2MMP3RAB9AMMP13 | |
| SCHEMBL7051208 | 0.81 | RXFP1 (0.49) | RXFP1PRNPKDM4EMMP1MMP2 | |
| SCHEMBL7048991 | 0.80 | MMP1 (0.52) | RXFP1PRNPKDM4EMMP1MMP2 | |
| SCHEMBL7049809 | 0.80 | PRNP (0.48) | RXFP1PRNPKDM4EMMP1MMP2 | |
| SCHEMBL7050282 | 0.80 | ACP3 (0.49) | MMP1MMP2MMP3MMP13ALDH1A1 | |
| SCHEMBL7048091 | 0.79 | RXFP1 (0.47) | RXFP1PRNPKDM4EMMP1MMP2 | |
| SCHEMBL7050067 | 0.78 | RXFP1 (0.45) | RXFP1PRNPKDM4EMMP1MMP2 | |
| SCHEMBL7049862 | 0.78 | KMT2A (0.47) | RXFP1PRNPKDM4EMMP1MMP2 | |
| SCHEMBL5053043 | 0.73 | MMP1 (0.61) | MMP1MMP2MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | disclosed |
| US-6579890-B1 | Matrix metalloprotease inhibitors | SYNTEX (U.S.A.) INC. | 2003-06-17 | — | — | US | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| EP-0726903-B1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX INC (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | RXFP1 738/4885PRNP 327/4885KDM4E 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.